Take a look at SGYP ... I bought the pullback there today. Tell me what you think of the chart?
Volume precedes price appreciation ... HUGE volume here.
Thanks to a few posters on the TROV board, I've been on the sidelines watching, but bought the pullback today.
"Interesting" board! ;-)
Saw that, too ... I don't think it will take too much more to jolt past our old high and into the $7s?
Another strong day of accumulation at, or near, $10!! What's not to like?
Still in CPXX with 1000 shares, but on a given day I will hold more than that. It's been a great trading stock. I originally had 3K but took some profits and added to TROV, as I said. Was lucky enough to be on the computer when that bear raid happened and I made a nice sum on 3K shares traded, which I put to work here, but jumped the gun a little, it seems. Didn't really want to discuss that on the CPXX board for various reasons. Are you in? The SOC piece should keep her afloat, I would think. GLTU
Still enjoying a honeymoon with investors following the release of impressive phase 3 data last month, Celator Pharmaceuticals (NASDAQ:CPXX) announced additional study data earlier this week that could further entrench its lead product candidate, Vyxeos, as the next standard of care in the treatment of acute myeloid leukemia.
Building a moat
Previously, Celator Pharmaceuticals Vyxeos extended overall survival in secondary AML to 9.56 months from 5.95 months for patients receiving the current standard of care: the 7 + 3 chemotherapy regimen.
Vyxeos extended overall survival without increasing safety risks and that performance could mean that Vyxeos, which is an optimized combination of the chemotherapy drugs used in the 7 + 3 approach, may enjoy widespread adoption if it's eventually approved by the Food and Drug Administration.
The 7 + 3 therapy, which is named for the duration of days patients receive the chemotherapy drugs cytarabine and daunorubicin, respectively, has been standard of care in AML for four decades and, sadly, little innovation in this indication means that AML survival rates remain far too low. According to the National Cancer Institute, 19,950 new cases of AML are diagnosed in the U.S. every year, and roughly three-quarters of AML patients succumb to their cancer within five years.
Given that backdrop, Vyxeos would seem to be the biggest advance in AML treatment in a generation; especially for tough to treat patients. Vyxeos results came in trials for use in secondary AML, or cases that stem from environmental, occupational, or therapeutic exposure to radiation. Secondary AML accounts for roughly 25% of all AML cases, and while over half of secondary AML patients respond to 7 + 3 as a first-line therapy, most secondary AML patients relapse and, despite intensive post-remission therapy, long term survival rates are only about 10%.
On Monday, the company presented additional data showing that Vyxeos could offer these patients new hope. Specifically, in ex-vivo studies, AML cells harboring the FLT3-ITD+ mutation removed from newly diagnosed AML patients responded strongly to Vyxeos.
Historically, the FLT3-ITD+ mutation has led to poor patient outcomes, yet in this study, AML cells exhibiting FLT3-ITD were roughly five times more sensitive to Vyxeos than cells were with normal FLT3. Since roughly 24% of AML patients exhibit a FLT3 mutation and roughly 27% to 34% of those patients exhibit the FLT3-ITD mutation, this finding is incredibly intriguing because it could give cancer centers more confidence to embrace it, rather than 7+3, in this subset of patients.
Celator Pharmaceuticals hasn't filed for FDA approval of Vyxeos yet, but it hopes to do so in the third quarter, and if it sticks with that timeline, then the FDA fast-tracked Vyxeos could win the regulatory green light in the second quarter of 2017. Assuming that it does, Vyxeos' effectiveness in AML patients could allow it to quickly capture a meaningful share of the AML treatment market. Since estimates value this market at $900 million by 2020, capturing even one-third of it would seem to justify a higher market cap for this company. For that reason, risk-tolerant investors might want to consider Celator Pharmaceuticals shares
Still plenty of selling here today ... seems odd, but what else is new?
Pretty steady accumulation at $10-ish today. Spend awhile consolidating and that 70 will deflate.
It will be interesting to see what has happened with institutional ownership.
Woo-hoo ... my $6.38 buy is looking a little better! I jest! I could care less ... we're in an uptrend and things are coming together!
Well, the good news is that I grabbed several thousand CPXX at about $13.75 and made some quick cash. The bad news is I added 2K TROV at $6.38! ;-)
The only way for the MMs to grab shares was to run the stops right at the open. Crafty little shysters!!
Well, over 300K volume here in 120 minutes off of that little maneuver!!
Has created an overhang here ... explosive volume of shares bought/sold leaves fewer buyers here ... profit-taking by those that bought the glitch, ... a little pressure on the IBB.
We'll just chew through all of that and create a nice strong base here in the $15's!! It's all good!
To keep things in perspective ... we were at $5 last week and $6 only a couple of days ago ... the MMs just took the wind out of the sales, albeit by pulling the rug out from under us!!
Well, I don't go that far back, but I, too, remember when 35K or so might change hands all morning. It was pretty easy to buy the orchestrated dips then, too!! ;-)
Not to mention some of the hot oil money is, and will, leave the sector and biotech is the natural recipient of some of the rotation, imo.
Decent volume here, though and not a lot of volatility. Smacks of news of some sort? Seems like someone always knows before us ... just sayin!
Wow ... when I posted, it was $14.80 ...screamed past $16 in a few minutes! Now the company issued a PR to clarify what the misconception was. I made some trading cash ... added 2K more TROV!!